acute myeloid leukemia aml
Leukemia clinical trials cover acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic myeloid leukemia (CML), and chronic lymphocytic leukemia (CLL) β€” distinct diseases with profoundly different biology and treatment approaches. AML research focuses on targeted agents for FLT3, IDH1/2, and TP53-mutated disease, while CLL trials explore fixed-duration venetoclax combinations that achieve treatment-free remissions.
Active trials investigate menin inhibitors for NPM1/KMT2A AML, magrolimab (anti-CD47) combinations, bispecific antibodies in relapsed ALL, and next-generation BTK inhibitors (pirtobrutinib) for ibrutinib-resistant CLL. MRD (minimal residual disease) negativity is emerging as a regulatory endpoint to accelerate approvals.
Disease Burden & Epidemiology
The leukemias collectively affect approximately 60,000 Americans annually, representing about 3% of all new cancer diagnoses. The four major subtypes have distinct epidemiology: Chronic lymphocytic leukemia (CLL) is the most common adult leukemia in Western countries, with approximately 20,000 new US cases annually and a median age at diagnosis of 70; Acute myeloid leukemia (AML) affects approximately 20,000 Americans annually with a median diagnosis age of 68 and one of the lowest five-year survival rates among hematologic malignancies (approximately 31% overall, falling to under 10% in elderly patients with adverse genetics); Chronic myeloid leukemia (CML) affects approximately 9,000 Americans annually but has been transformed by BCR-ABL1 tyrosine kinase inhibitors (TKIs) from a uniformly fatal disease to one with near-normal life expectancy in most patients; Acute lymphoblastic leukemia (ALL) affects approximately 6,000 Americans annually, with peak incidence in children (5-year survival >90%) and a markedly poorer prognosis in adults (5-year survival ~35% before modern immunotherapy). Genetic alterations drive all leukemia subtypes, and comprehensive genomic testing is now standard at diagnosis to guide treatment selection and clinical trial eligibility.
Key Research Trends & Landmark Studies
In CLL, the MURANO trial established venetoclax-rituximab as a fixed-duration regimen achieving 57% undetectable MRD rates at treatment completion, fundamentally changing treatment goals from chronic management to potential functional cure. The CLL14 trial extended this approach to venetoclax-obinutuzumab for treatment-naive patients. In AML, the VIALE-A trial established venetoclax plus azacitidine as the new standard for older or unfit AML patients, improving complete remission rates from 28% to 66% versus azacitidine alone. IDH1/2 inhibitors (ivosidenib, enasidenib, olutasidenib) have established mutation-targeted therapy as feasible in AML, and menin inhibitors (revumenib) have achieved 23% complete remission in heavily pretreated NPM1/KMT2A AML β€” the fastest-growing area of current AML drug development. In ALL, blinatumomab and inotuzumab ozogamicin have transformed relapsed/refractory B-ALL, and CAR-T cell therapies (tisagenlecleucel) have achieved durable remissions in pediatric and young adult ALL. For CML, the EURO-SKI and STOP-TKI trials established that approximately 50% of patients achieving deep molecular response can safely discontinue TKI therapy β€” a major quality-of-life advance.
Patient Guide: How to Find & Join a Trial
Patients with any leukemia subtype should seek evaluation at an academic hematology-oncology center at diagnosis, as the breadth of genomic testing required and the complexity of treatment decisions — particularly trial matching — require subspecialty expertise. For newly diagnosed AML, genetic and molecular testing (cytogenetics, FLT3, NPM1, IDH1/2, TP53, and ASXL1) must be completed before treatment initiation to determine trial eligibility and to guide standard-of-care drug selection. This testing typically requires 5–10 business days; be aware that some acute leukemia trials require enrollment within days of diagnosis, and treatment delays for testing may impact eligibility. For CLL patients, watch-and-wait remains appropriate for early-stage asymptomatic disease, during which time enrollment in prevention and biomarker trials is possible. All leukemia patients should request a consultation at their institution's clinical trials office after diagnosis — leukemia has among the highest proportion of trial-eligible patients of any cancer type, and trial participation rates exceed 30% at academic centers.